These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 215543)

  • 1. Protection against Marek's disease-derived tumor transplants by the nononcogenic SB-1 strain of Marek's disease virus.
    Schat KA; Calnek BW
    Infect Immun; 1978 Oct; 22(1):225-32. PubMed ID: 215543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an apparently nononcogenic Marek's disease virus.
    Schat KA; Calnek BW
    J Natl Cancer Inst; 1978 May; 60(5):1075-82. PubMed ID: 76680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the bursa of Fabricius on the pathogenesis of Marek's disease.
    Schat KA; Calnek BW; Fabricant J
    Infect Immun; 1981 Jan; 31(1):199-207. PubMed ID: 6260660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide-induced amelioration of Marek's disease in Marek's disease-susceptible chickens.
    Lu YS; Kermani-Arab V; Moll T
    Am J Vet Res; 1976 Jun; 37(6):687-92. PubMed ID: 180852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired host resistance against local JMV Marek's disease tumors after thymectomy and after bursectomy.
    Lam KM; Linna TJ
    Adv Exp Med Biol; 1982; 149():679-85. PubMed ID: 6293284
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of B-cell immunosuppression on age-related resistance of chickens to Marek's disease.
    Sharma JM; Witter RL
    Cancer Res; 1975 Mar; 35(3):711-7. PubMed ID: 234791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of a transplantable Marek's disease lymphoma in normal versus immunologically deficient chickens.
    Calnek BW; Fabricant J; Schat KA; Murthy KK
    J Natl Cancer Inst; 1978 Mar; 60(3):623-31. PubMed ID: 304897
    [No Abstract]   [Full Text] [Related]  

  • 8. Towards a mechanistic understanding of the synergistic response induced by bivalent Marek's disease vaccines to prevent lymphomas.
    Umthong S; Dunn JR; Cheng HH
    Vaccine; 2019 Oct; 37(43):6397-6404. PubMed ID: 31515142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early infection with Marek's disease virus can jeopardize protection conferred by laryngotracheitis vaccines: a method to study MDV-induced immunosuppression.
    Faiz NM; Cortes AL; Guy JS; Fletcher OJ; West M; Montiel E; Gimeno IM
    Avian Pathol; 2016 Dec; 45(6):606-615. PubMed ID: 27207594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pathogenesis studies with oncogenic and nononcogenic Marek's disease viruses and turkey herpesvirus.
    Calnek BW; Carlisle JC; Fabricant J; Murthy KK; Schat KA
    Am J Vet Res; 1979 Apr; 40(4):541-8. PubMed ID: 229747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of Marek's disease; effect of immunization with inactivated viral and tumor-associated antigens.
    Murthy KK; Calnek BW
    Infect Immun; 1979 Nov; 26(2):547-53. PubMed ID: 232690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nonproducer T lymphoblastoid cell line from Marek's disease transplantable tumor (JMV).
    Nazerian K; Stephens EA; Sharma JM; Lee LF; Gailitis M; Witter RL
    Avian Dis; 1977; 21(1):69-76. PubMed ID: 190995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Field trials with a bivalent vaccine (HVT and SB-1) against Marek's disease.
    Calnek BW; Schat KA; Peckham MC; Fabricant J
    Avian Dis; 1983; 27(3):844-9. PubMed ID: 6314982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinal efficacy of molecularly cloned
    Kim T; Spatz SJ; Dunn JR
    J Gen Virol; 2020 May; 101(5):542-552. PubMed ID: 32134378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus.
    Nazerian K; Lee LF; Yanagida N; Ogawa R
    J Virol; 1992 Mar; 66(3):1409-13. PubMed ID: 1310755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune responses to inactivated oil-emulsified Marek's disease vaccine.
    Lee LF; Witter RL
    Avian Dis; 1991; 35(3):452-9. PubMed ID: 1659363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.
    Sonoda K; Sakaguchi M; Okamura H; Yokogawa K; Tokunaga E; Tokiyoshi S; Kawaguchi Y; Hirai K
    J Virol; 2000 Apr; 74(7):3217-26. PubMed ID: 10708438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Marek's disease virus type 1 provides full protection against very virulent Marek's and infectious bursal disease viruses in chickens.
    Li K; Liu Y; Liu C; Gao L; Zhang Y; Cui H; Gao Y; Qi X; Zhong L; Wang X
    Sci Rep; 2016 Dec; 6():39263. PubMed ID: 27982090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demonstration of Marek's disease tumor-associated surface antigen in chickens infected with nononcogenic Marek's disease virus and herpesvirus of turkeys.
    Schat KA; Calnek BW
    J Natl Cancer Inst; 1978 Sep; 61(3):855-7. PubMed ID: 211242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant fowlpox virus vaccines against Australian virulent Marek's disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens.
    Heine HG; Foord AJ; Young PL; Hooper PT; Lehrbach PR; Boyle DB
    Virus Res; 1997 Jul; 50(1):23-33. PubMed ID: 9255932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.